1. ALLA AKTIER
  2. NYHETER
  3. XINTELA

Xintela

Nyheter Xintela Nyheter alla bolag

Xintela AB Interim Report January - March 2023

MARKN.

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

First quarter 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 15,843 (loss: 16,383).
Loss per share* was SEK 0.05 (loss: 0.18).
 
First quarter 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before and after tax totalled TSEK 10,403 (loss: 11,042).
Loss per share* was SEK 0.03 (loss: 0.12).
At March 31, 2023, the equity/assets ratio** was 45 % (0).
 
Significant events in the first quarter of 2023
» Xintela completes dosing of XSTEM second dose level in knee osteoarthritis clinical study. (March 3, 2023)

Significant events after the end of the period
» Xintela has started last dose level of XSTEM in knee osteoarthritis clinical study. (April 13, 2023)
» Communiqué from the Annual General Meeting of Xintela AB (publ). (May 12, 2023)
» Xintela is carrying out a Rights issue of units of approximately SEK 123 million. (May 24, 2023)
 
The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB.

Attachments

Xintela Q1 2023 EN

Datum 2023-05-25, kl 08:00
Källa MFN
Bifogade filer
Xintela Q1 2023 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!